Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Anti-HER2 Therapy for Metastatic Breast Cancer

July 21st 2015

PI3K Inhibition in Breast Cancer

July 21st 2015

Overcoming Endocrine Resistance in Breast Cancer

July 21st 2015

CDK4/6 Inhibition in Breast Cancer

July 21st 2015

Advancements in ER-Positive Breast Cancer

July 21st 2015

Guiding Treatment With Molecular Testing in Breast Cancer

July 21st 2015

Efforts Continue to Refine Neoadjuvant HER2+ Breast Cancer Care

July 21st 2015

Douglas Yee, MD, explains current treatment options and ongoing research aimed at optimizing neoadjuvant therapy for HER2-positive breast cancer.

Dr. Kass on Testing for HER2-Positive Breast Cancer

July 20th 2015

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, gives advice for community-based oncologists regarding HER2 testing and interpretation of the results.

Dr. Nanda on Immunotherapy in Metastatic TNBC

July 18th 2015

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.

Dr. Chlebowski on Dietary Modifications in Patients With Breast Cancer

July 17th 2015

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California, Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses a planned follow-up analysis of the Women's Health Initiative Dietary Modification study, which examined the impact of reduced dietary fat intake in patients with breast cancer.

Everolimus Activity Linked With PIK3CA/PTEN Status in HER2-Positive Breast Cancer

July 16th 2015

PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.

Neoadjuvant T-DM1 Shows Promising pCR Rates in HER2+/HR+ Early Breast Cancer

June 23rd 2015

Chemotherapy-free neoadjuvant treatment with trastuzumab emtansine demonstrated a pathological complete response rate of 40.5% in patients with HER2+ and HR+ early breast cancer.

O'Regan Discusses Breast Cancer Index, Molecular Profiling in HER2+ Breast Cancer

June 23rd 2015

Ruth M. O'Regan, MD, discusses two of her studies in HER2-positive breast cancer presented at ASCO 2015.

Dr. Esteva Discusses T-DM1 in HER2-Positive Breast Cancer

June 22nd 2015

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, associate director, Clinical Investigation Perlmutter Cancer Center, director, Breast Medical Oncology Program, NYU Langone Medical Center, discusses the efficacy of T-DM1 in patients with HER2-positive breast cancer.

Adjuvant Radiotherapy in Low-Risk Breast Cancer Patients: Review and Clinical Implications

June 21st 2015

Over the past several decades, breast-conserving therapy has emerged as the standard of care in the management of early-stage breast cancer.

Novel Small Molecule Inhibitor Shows Promise in HER2+ Breast Cancer With CNS Metastases

June 17th 2015

For insight on the potential of ONT-380 in HER2-positive breast cancer, OncLive spoke with the lead author of the primary phase Ib analysis, Erika P. Hamilton, MD.

Future Approaches in Breast Cancer

June 17th 2015

TNT Study for Triple-Negative or BRCA1/2 Breast Cancer

June 17th 2015

Neratinib in HER2-Positive Breast Cancer

June 17th 2015

Clinical Trials for HER2-Positive Breast Cancer

June 17th 2015